Novartis (NVS) reported positive topline results from twice-yearly Leqvio in the Phase III V-MONO study, which met primary endpoints. In the study, Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.

诺华（Novartis）在III期V-MONO研究中报告了每年两次的Leqvio阳性结果，该研究符合主要终点。在这项研究中，与安慰剂和依折麦布相比，Leqvio单一疗法在发生动脉粥样硬化性心血管疾病的低或中度风险且未接受降脂治疗的患者中实现了具有临床意义和统计学意义的低密度脂蛋白胆固醇降低。

Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis, said: 'This trial adds to the growing body of evidence for Leqvio across the full spectrum of ASCVD as we strive to help more patients in need.'Novartis plans to present results from the trial at an upcoming medical meeting and share with regulatory agencies including the FDA.

诺华公司总裁、发展和首席医疗官Shreeram Aradhye说：“随着我们努力帮助更多需要帮助的患者，这项试验在整个ASCVD范围内为Leqvio提供了越来越多的证据。”诺华计划在即将举行的医学会议上公布试验结果，并与包括FDA在内的监管机构分享。